Antiretroviral drug-related toxicities-clinical spectrum, prevention, and management

Expert Opinion on Drug Safety

Volumn 12, Issue 5, 2013, Pages 697-707

  Fernandez Montero, Jose V ^a   Eugenia, Eugenia ^a   Barreiro, Pablo ^a   Labarga, Pablo ^a   Soriano, Vicente ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antiretroviral drugs; Hepatitis; HIV; Rash; Toxicity

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; CORTICOSTEROID; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADVERSE DRUG REACTION; ANTIVIRAL THERAPY; ASTHENIA; BONE DISEASE; BONE MARROW TOXICITY; CORTICOSTEROID THERAPY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEART MUSCLE CONDUCTION DISTURBANCE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; MENTAL DISEASE; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; NAUSEA; NEPHROLITHIASIS; NEPHROTOXICITY; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TOXIC HEPATITIS; UPPER RESPIRATORY TRACT INFECTION;

ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIV INFECTIONS; HUMANS;

EID: 84883044960     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.806480     Document Type: Review

References (92)

1. Palella F, Baker R, Moorman A, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43:27-34
2. Kitahata M, Gange S, Abraham A, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009;360:1815-26
3. Cohen M, Chen Y, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505
4. Thompson M, Aberg J, Hoy J, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308:387-402
5. Rockstroh J, Lennox J, De Jesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive HIV-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011;53:807-16
6. Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-na?ve, HIV-1 patients in two Phase III randomised trials. AIDS 2012:In press
7. van Lunzen J, Maggiolo F, Arribas J, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012;12:111-18
8. Sax P, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012;379:2439-48
9. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a Public Health approach: 2010 revision. Available from: http://www.who.int/hiv/pub/arv/adult2010/en/index.html [Last accessed April 17][2013]
10. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: swiss HIV Cohort Study. Lancet 2001;358:1322-7
11. Keiser O, Fellay J, Opravil M, et al. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. Antiviral Ther 2007;12:1157-64
12. Collier A, Coombs R, Schoenfeld D, et al. Treatment of HIV infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-18
13. Hammer S, Squires K, Hughes M, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with HIV infection and CD4 cell counts of 200 per mm3 or less. N Engl J Med 1997;337:725-33
14. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372:646-55
15. Orkin C, De Jesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-na?ve patients in the ARTEMIS trial. HIV Med 2013;14:49-59
16. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from: http://aidsinfo. nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf [Last accessed April 17 2013]
17. Riddler S, Haubrich R, Di Rienzo G, et al. Class-Sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-106
18. Soriano V, Arasteh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN trial. Antivir Ther 2011;16:339-48
19. Katlama C, Clotet B, Mills A, et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther 2010;15:1045-52
20. Wilkin A, Pozniak AL, Morales-Ramirez J, et al. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses 2012;28:437-46
21. Sierra-Madero J, Di Perri G, Wood R, et al. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials 2010;11:125-32
22. Chowers M, Gottesman B, Leibovici L, et al. Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2010;29:779-86
23. Sax P, Tierney C, Collier A, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011;204:1191-201
24. Lewis W, Dalakas M. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417-22
25. Walker U, Bauerle J, Laguno M, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004;39:311-17
26. Palacios R, Aguilar J, Hidalgo A, et al. Didanosine, lamivudine- emtricitabine and efavirenz as initial therapy in na?ve patients. Expert Rev Anti Infect Ther 2006;4:965-71
27. Cote H, Brumme Z, Craib K, et al. Changes in mitochondrial DNA as markers of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811-20
28. Lactic acidosis International study group. Risk factors for lactic acidosis and severe hyperlactatemia in HIV-1 infected adults exposed to antiretroviral therapy. AIDS 2007;21:2455-64
29. Cihlar T, Ray A. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res 2010;85:39-58
30. Gallant J, De Jesus E, Arribas J, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-60
31. Saag M, Sonnerborg A, Torres R, et al. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. AIDS 1998;12:F203-9
32. Mallal L, Nolan D, Witt C, et al. Association between presence of HLA B-5701, HLA- DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 2002;359:727-32
33. Mallal S, Phillips E, Carosi G, et al. HLA-B5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79
34. Sabin C, Worm S, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417-26
35. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011;25:1993-2004
36. Ribaudo H, Benson C, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 2011;52:929-40
37. Barreiro P, Soriano V, Casas E, et al. Prevention of nevirapine- associated exanthema using slow dose escalation and/or corticosteroids. AIDS 2000;14:2153-7
38. Havlir D, Cheeseman S, McLoughlin M, et al. High-dose nevirapine: safety, pharmacokinetics and antiviral effect in patients with HIV infection. J Infect Dis 1995;171:537-45
39. Knobel H, Guelar A, Montero M, et al. Risk of side effects associated with the use of nevirapine in treatment-na?ve patients, with respect to gender and CD4 cell count. HIV Med 2008;9:14-18
40. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother 2009;64:910-28
41. Staszewski S, Morales-Ramirez J, Tashima K, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-73
42. Munoz-Moreno J, Fumaz C, Ferrer M, et al. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates and management. A neurobehavioral review. AIDS Rev 2009;11:103-9
43. Nunez M, Gonzalez de Requena D, Gallego L, et al. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 2001;28:399-400
44. Gallego L, Barreiro P, del R?o R, et al. Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz. Clin Infect Dis 2004;38:430-2
45. Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. AIDS Rev 2010;12:67-75
46. Rivero A, Mira J, Pineda J, et al. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007;59:342-6
47. Abrescia N, Abbraccio M, Figoni M, et al. Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a treatment na?ve female AIDS patient without hepatitis virus co-infection. J Antimicrob Chemother 2002;50:763-5
48. Girard P, Campbell T, Grinsztejn B, et al. Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest. HIV Med 2012;13:427-35
49. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009;23:2289-300
50. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase III randomized double-blind active-controlled trial. Lancet 2011;378:238-46
51. Fernandez-Montero JV, Vispo E, Anta L, et al. Rilpivirine: a next-generation nonnucleoside analogue for the treatment of HIV infection. Expert Opin Pharmacother 2012;13:1007-14
52. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality in an ambulatory HIV-infected population. N Engl J Med 1998;338:853-60
53. Naggie S, Hicks C. Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options. J Antimicrob Chemother 2010;65:1094-9
54. Johnson M, Gathe J, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides non-inferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2013;43:153-60
55. Fernandez-Montero JV, Barreiro P, Soriano V. HIV protease inhibitors: recent clinical trials and recommendations on use. Expert Opin Pharmacother 2009;10:1615-29]
56. Bongiovanni M, Bini T, Cicconi P, et al. Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir. AIDS Res Hum Retroviruses 2006;22:132-8
57. Soriano V, Garcia-Gasco P, Vispo E, et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother 2008;61:200-5
58. Pulido F, Estrada V, Baril J, et al. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 Weeks. HIV Clin Trials 2009;10:76-87
59. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010;53:323-32
60. Artacho MA, Barreiro P, Fernandez-Montero JV. Long-term treatment of patients with HIV-1: the role of atazanavir. HIV AIDS (Auckl) 2010;2:157-66
61. Rivas P, Morello J, Garrido C, et al. Role of atazanavir in the treatment of HIV infection. Ther Clin Risk Manag 2009;5:99-116
62. Ortiz R, De Jesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-na?ve HIV-1-infected patients at week 48. AIDS 2008;22:1389-97
63. Moyle G, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001;2:105-13
64. Raffi F, Rachlis A, Stellbrink H, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013;381:735-43
65. Rockstroh J, De Jesus E, Henry K, et al. A randomized, double-blind comparison of elvitegravir/cobicistat/emtricitabine/tenofovir versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013
66. Martins C. Cutaneous drug reactions associated with newer antiretroviral agents. J Dermatol 2006;5:976-82
67. Soriano V, Puoti M, Garcia-Gasco P, et al. Antiretroviral drugs and liver injury. AIDS 2008;22:1-13
68. Jones M, Nunez M. Liver toxicity of antiretroviral drugs. Semin Liver Dis 2012;32:167-76
69. Sulkowski M, Thomas D, Mehta S, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;35:182-9
70. Barreiro P, Soriano V, Blanco F, et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV infected subjects under long-term successful triple combination therapy. AIDS 2000;14:807-12
71. Domingo P, Labarga P, Palacios R, et al. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS 2004;18:1745-8
72. Blanco F, San Roman J, Vispo E, et al. Management of metabolic complications and cardiovascular risk in HIV-infected patients. AIDS Rev 2010;12:231-41
73. Noor M, Seneviratne T, Aweeka F, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002;16:F1-8
74. Tebas P. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options. J Acquir Immune Defic Syndr 2008;49(Suppl):86-92
75. Gallego L, Barreiro P, Lopez-Ibor JJ. Diagnosis and clinical features of major neuropsychiatric disorders in HIV infection. AIDS Rev 2011;13:171-9
76. Munoz-Moreno J, Fumaz C, Ferrer M, et al. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates and management. A neurobehavioral review. AIDS Rev 2009;11:103-9
77. Nelson M, Stellbrink H, Podzamczer D, et al. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS 2011;25:335-40
78. Gallego L, Barreiro P, Lopez-Ibor JJ. Psychopharmacological treatments in HIV patients under antiretroviral therapy. AIDS Rev 2012;14:101-11 Available from: www.hivdruginteractions. org/
79. Kotler D. HIV infection and the gastrointestinal tract. AIDS 2005;19:107-17
80. Hill A, Balkin A. Risk factors for gastrointestinal adverse events in HIV treated and untreated patients. AIDS Rev 2009;11:30-8
81. Izzedine H, Launay-Vacher V, Deray G. Renal tubular transporters and antiviral drugs: an update. AIDS 2005;19:455-62
82. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009;23:689-96
83. Rodriguez-Novoa S, Labarga P, D'Avolio A, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 2010;24:1064-6
84. Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 2004;18:960-3
85. Ryom L, Mocroft A, Kirk O, et al. Exposure to antiretrovirals (ARVs) and risk of renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis 2013;207:1359-69
86. Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic substudy. Clin Infect Dis 2009;48:e108-16
87. German P, Liu H, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 2012;61:32-40
88. de Lastours V, Ferrari Rafael De Silva E, Daudon M, et al. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother 2013:In press
89. Hamada Y, Nishijima T, Watanabe K, et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis 2012;55:1262-9
90. Mocroft A, Staszewski S, Weber R, et al. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and experienced HIV-infected patients with high and low CD4+ T-cell counts. Antivir Ther 2007;12:325-33
91. De Lazzari E, Leon A, Arnaiz J, et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. HIV Med 2008;9:221-6
92. Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS 2013:In press